Effectiveness of Medical Treatment of Cushing's Disease: A Systematic Review and Meta-Analysis

被引:23
作者
Simoes Correa Galendi, Julia [1 ,2 ]
Correa Neto, Afonso Nogueira Simoes [3 ]
Demetres, Michelle [4 ]
Boguszewski, Cesar Luiz [5 ]
Nogueira, Vania dos Santos Nunes [6 ]
机构
[1] Univ Cologne, Fac Med, Cologne, Germany
[2] Univ Hosp Cologne, Inst Hlth Econ & Clin Epidemiol, Cologne, Germany
[3] Univ Fed Minas Gerais, Sch Med, Belo Horizonte, MG, Brazil
[4] Weill Cornell Med, Samuel J Wood Lib & CV Starr Biomed Informat Ctr, New York, NY USA
[5] Univ Fed Parana, Dept Internal Med, Endocrine Div SEMPR, Curitiba, Parana, Brazil
[6] Sao Paulo State Univ, UNESP, Sch Med, Dept Internal Med, Botucatu, SP, Brazil
关键词
Cushing's disease; pasireotide (SOM230); cabergoline; ketoconazole; metyrapone; systematic literature review; meta-analysis; LONG-TERM REMISSION; QUALITY-OF-LIFE; KETOCONAZOLE TREATMENT; STEROIDOGENESIS INHIBITORS; PASIREOTIDE; EFFICACY; THERAPY; CABERGOLINE; MANAGEMENT; MULTICENTER;
D O I
10.3389/fendo.2021.732240
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
Objective:& nbsp;The objective of this systematic review was to evaluate the effectiveness and safety of pasireotide, cabergoline, ketoconazole, levoketoconazole, metyrapone, osilodrostat, and temozolomide for the treatment of Cushing's disease (CD).</p> </p> Methods:& nbsp;The primary outcomes were the proportion of CD control, adverse events (AE), and reduction of urinary free cortisol. Search strategies were applied to Embase, Medline, and CENTRAL. Independent reviewers assessed the study eligibility, extracted data, and evaluated risk of bias. Standardized mean difference was calculated with 95% confidence interval (CI) for continuous data (i.e., pre- and post-intervention). Random meta-analyses for the proportion of CD control and AE were conducted.</p> </p> Results:& nbsp;Twenty-nine controlled and non-controlled studies were included. No study with temozolomide and levoketoconazole and one study with osilodrostat fulfilled the inclusion criteria. The meta-analyses of proportion of CD control was 35% for cabergoline (95% CI: 27-43%, six studies, 141 participants), 44% for pasireotide (95% CI: 25-35%, eight studies, 522 participants), 41% for ketoconazole (95% CI: 36-46%, six studies, 450 participants), 66% for metyrapone (95% CI: 46-87%, four studies, 66 participants), and of 66.4% for osilodrostat (95% CI: 57.9, 74.3, 97 participants, one study). One study compared two different treatments (cabergoline vs. ketoconazole), and no statistical difference was observed in CD control (RR: 0.53, 95% CI: 0.15 to 1.87, 14 participants, very low certainty of evidence). The most frequent AE associated with pasireotide was hyperglycemia, dizziness and nausea with cabergoline and metyrapone, and elevated transaminases with ketoconazole.</p> </p> Conclusion:& nbsp;The superiority of one drug over another could not be determined due to lack of controlled studies, but the proportion of disease control identified in our meta-analysis may support clinical decision. New therapeutic options should be investigated due to the limited efficacy and tolerability of the currently available medical treatment for patients with Cushing's disease.</p>
引用
收藏
页数:12
相关论文
共 79 条
[1]   Pasireotide treatment reduces cardiometabolic risk in Cushing's disease patients: an Italian, multicenter study [J].
Albani, A. ;
Ferrau, F. ;
Ciresi, A. ;
Pivonello, R. ;
Scaroni, C. ;
Iacuaniello, D. ;
Zilio, M. ;
Guarnotta, V. ;
Alibrandi, A. ;
Messina, E. ;
Boscaro, M. ;
Giordano, C. ;
Colao, A. ;
Cannavo, S. .
ENDOCRINE, 2018, 61 (01) :118-124
[2]   Long-term remission and recurrence rates in Cushing's disease: predictive factors in a single-centre study [J].
Alexandraki, Krystallenia I. ;
Kaltsas, Gregory A. ;
Isidori, Andrea M. ;
Storr, Helen L. ;
Afshar, Farhad ;
Sabin, Ian ;
Akker, Scott A. ;
Chew, Shern L. ;
Drake, William M. ;
Monson, John P. ;
Besser, G. Michael ;
Grossman, Ashley B. .
EUROPEAN JOURNAL OF ENDOCRINOLOGY, 2013, 168 (04) :639-648
[3]   GRADE guidelines: 3. Rating the quality of evidence [J].
Balshem, Howard ;
Helfand, Mark ;
Schuenemann, Holger J. ;
Oxman, Andrew D. ;
Kunz, Regina ;
Brozek, Jan ;
Vist, Gunn E. ;
Falck-Ytter, Yngve ;
Meerpohl, Joerg ;
Norris, Susan ;
Guyatt, Gordon H. .
JOURNAL OF CLINICAL EPIDEMIOLOGY, 2011, 64 (04) :401-406
[4]   Combination therapy for Cushing's disease: effectiveness of two schedules of treatment. Should we start with cabergoline or ketoconazole? [J].
Barbot, M. ;
Albiger, N. ;
Ceccato, F. ;
Zilio, M. ;
Frigo, A. C. ;
Denaro, L. ;
Mantero, F. ;
Scaroni, C. .
PITUITARY, 2014, 17 (02) :109-117
[5]   Effects of pasireotide treatment on coagulative profile: a prospective study in patients with Cushing's disease [J].
Barbot, Mattia ;
Guarnotta, Valentina ;
Zilio, Marialuisa ;
Ceccato, Filippo ;
Ciresi, Alessandro ;
Daniele, Andrea ;
Pizzolanti, Giuseppe ;
Campello, Elena ;
Frigo, Anna Chiara ;
Giordano, Carla ;
Scaroni, Carla .
ENDOCRINE, 2018, 62 (01) :207-214
[6]   Outcomes of therapy for Cushing's disease due to adrenocorticotropin-secreting pituitary macroadenomas [J].
Blevins, LS ;
Christy, JH ;
Khajavi, M ;
Tindall, GT .
JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM, 1998, 83 (01) :63-67
[7]   Extended treatment of Cushing's disease with pasireotide: results from a 2-year, Phase II study [J].
Boscaro, M. ;
Bertherat, J. ;
Findling, J. ;
Fleseriu, M. ;
Atkinson, A. B. ;
Petersenn, S. ;
Schopohl, J. ;
Snyder, P. ;
Hughes, G. ;
Trovato, A. ;
Hu, K. ;
Maldonado, M. ;
Biller, B. M. K. .
PITUITARY, 2014, 17 (04) :320-326
[8]   Treatment of Pituitary-Dependent Cushing's Disease with the Multireceptor Ligand Somatostatin Analog Pasireotide (SOM230): A Multicenter, Phase II Trial [J].
Boscaro, M. ;
Ludlam, W. H. ;
Atkinson, B. ;
Glusman, J. E. ;
Petersenn, S. ;
Reincke, M. ;
Snyder, P. ;
Tabarin, A. ;
Biller, B. M. K. ;
Findling, J. ;
Melmed, S. ;
Darby, C. H. ;
Hu, K. ;
Wang, Y. ;
Freda, P. U. ;
Grossman, A. B. ;
Frohman, L. A. ;
Bertherat, J. .
JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM, 2009, 94 (01) :115-122
[9]   Approach to the Patient with Possible Cushing's Syndrome [J].
Boscaro, Marco ;
Arnaldi, Giorgio .
JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM, 2009, 94 (09) :3121-3131
[10]   Effectiveness of medical treatment for Cushing's syndrome: a systematic review and meta-analysis [J].
Broersen, Leonie H. A. ;
Jha, Meghna ;
Biermasz, Nienke R. ;
Pereira, Alberto M. ;
Dekkers, Olaf M. .
PITUITARY, 2018, 21 (06) :631-641